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Rapport de synthèse : 
«Etiologie de la pneumonie communautaire chez l'enfant hospitalisé selon les critères de 
l'OMS ». 
Enjeux de la recherche: La pneumonie communautaire chez l'enfant est un problème de 
santé publique considérable. Elle est responsable de 2 millions de mort par année, 70% 
survenant dans les pays en voie de développement. Sous nos latitudes son incidence est de 
40/1000 enfants par année, ce qui représente une morbidité importante. Deux difficultés 
surviennent lorsqu'on cherche à diagnostiquer une pneumonie. La première est de distinguer 
une pneumonie bactérienne d'une virale, particulièrement chez les petits enfants où les 
infections virales des voies respiratoires inférieures sont fréquentes. L'OMS a définit la 
pneumonie selon des critères exclusivement cliniques et une étude effectuée à Lausanne en 
2000 a montré que ces critères peuvent être utilisés dans nos contrées. La seconde difficulté 
est de définir l'agent causal de la pneumonie, ceci pour plusieurs raisons : L'aspiration 
endotrachéale, seul examen fiable, ne peut être obtenue de routine chez l'enfant vu son 
caractère invasif, la culture des secrétions nasopharyngées reflète la flore physiologique de la 
sphère ORL et une bactériémie n'est présente que dans moins de 10% des pneumonies. 
L'étiologie de la pneumonie reste souvent inconnue, et de ce fait plusieurs enfants reçoivent 
des antibiotiques pour une infection non bactérienne ce qui contribue au développement de 
résistances. L'objectif de cette étude était d'effectuer une recherche extensive de l'agent 
causal de la pneumonie et de déterminer quels facteurs pourraient aider le clinicien à 
différencier une pneumonie virale de bactérienne, en corrélant l'étiologie avec la sévérité 
clinique et les marqueurs de l'inflammation. 
Contexte de la recherche: Il s'agissait d'une étude prospective, multicentrique, incluant les 
enfants âgés de 2 mois à 5 ans hospitalisés pour une pneumonie, selon les critères de l'OMS, 
dans le service de pédiatrie de Lausanne et Genève entre mars 2003 et Décembre 2005, avant 
l'implantation de la vaccination antipneumococcique de routine. Chaque enfant, en plus des 
examens usuels, bénéficiait d'une recherche étiologique extensive : Culture virale et 
bactérienne, PCR (Mycoplasma Pneumoniae, Chlamydia Pneumoniae, Virus Influenza A et 
B, RSV A et B, Rhinovirus, Parainfluenza 1-3, enterovirus, human metapneumovirus, 
coronavirus OC43, E229 ; et NL 63) et détection d' AG viraux dans les sécrétions 
nasopharyngées ; sérologies virales et bactériennes à l'entrée et 3 semaines après la sortie 
(AG Influenza A et B, Parainfluenza 1,2 et 3, RSV, Adenovirus, MPneumoniae et 
S.Pneumoniae). 
Conclusions : Un agent pathogène a été découvert chez 86% des 99 patients retenus 
confirmant le fait que plus la recherche étiologique est étendue plus le pourcentage d'agent 
causal trouvé est élevé. Une infection bactérienne a été découvert chez 53% des patients dont 
45% avaient une infection à S. Pneumoniae confirmant l'importance d'une vaccination 
antipneumococcique de routine. La déshydratation et les marqueurs de l'inflammation tels 
que la C-Reactive Protein et la Procalcitonine étaient significativement plus élevés dans les 
pneumonies bactériennes. Aucune corrélation n'a été trouvée entre le degré de sévérité de la 
pneumonie et l'étiologie. L'étude a confirmé la haute prévalence d'infections virales (67%) et 
de co-infection (33%) dans la pneumonie de'l'enfant sans que l'on connaisse le rôle réel du 
virus dans la pathogenèse de la pneumonie. 
Perspectives : D'autres études à la suite de celle-ci devraient être effectuées en incluant les 
patients ambulatoires afin de déterminer, avec un collectif plus large de patient, une 
éventuelle corrélation entre sévérité clinique et étiologie. 
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Abstract Community-acquired pneumonia (CAP) is a ma-
jor cause of death in developing countries and of morbidity 
in developed countries. The objective of the study was to 
define the causative agents among children hospitalized for 
CAP defined by WHO guidelines and to correlate etiology 
with clinical severity and surrogate markers. Investigations 
included an extensive etiological workup. A potential 
causative agent was detected in 86% of the 99 enrolled 
patients, with evidence of bacterial (53%), viral (67%), and 
mixed (33%) infections. Streptococcus pneumoniae was 
accounted for in 46% of CAP. Dehydration was the only 
clinical sign associated with bacterial pneumonia. CRP and 
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PCT were significantly higher in bacterial infections. 
Increasing the number of diagnostic tests identifies potential 
causes of CAP in up to 86% of children, indicating a high 
prevalence of viruses and frequent co-infections. The high 
proportion of pneumococcal infections re-emphasizes the 
importance of pneumococcal immunization. 
Keywords Community-acquired pneumonia · Child · 
WHO guidelines · Pneumococcal infection · Antibiotic · 
Immunization 
Abbreviations 
CAP Community-acquired pneumonia 
WHO World Health Organization 
CRP C-reactive protein 
PCT Procalcitonin 
NPA Nasopharyngeal aspirates 
BTS British Thoracic Society 
NS Nasopharyngeal swabs 
WBC White blood cell 
URS Upper respiratory symptoms 
hMPV Human metapneumovirus 
Introduction 
Childhood community-acquired pneumonia (CAP) is a 
common and serions health care problem, responsible for 
one fifth of children's deaths around the world (2 million), 
70% occurring in developing countries [ 45]. In Europe and 
North America, the annual incidence of CAP is approxi-
mately 40 cases per 1,000 and therefore also represents a 
major cause of morbidity [19]. There are two major 
difficulties in the diagnosis of CAP. The first one is how 
to define pneumonia, particularly in the young age group in 
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which both pneumonia and viral lower respiratory tract 
infections are common conditions. The World Health 
Organization (WHO) has defined pneumonia and subse-
quent treatment on strict clinical signs (Table 1) [l, 7, 17]. 
A prospective study showed that the WHO guidelines can 
also be applied in developed countries, as recommended by 
the guide lin es of the British Thoracic Society (BTS) [2, 11]. 
The second difficulty is to identify the causative agent of 
pneumonia in children. This remains challenging for a 
number of reasons: endo-tracheal aspirates cannot be 
obtained routinely, nasopharyngeal swabs (NS) only show 
colonization by normal flora including the bacteria most 
commonly causing pneumonia, and bacteremia is demon-
strated in less than 10% of bacterial CAP. Therefore, the 
etiology of CAP remains often unknown, with the 
consequence that many children get an antibiotic treatment 
for non-bacterial infections, contributing to the increase of 
bacterial resistance to antibiotics [9, 41 ]. The aims of this 
study, performed before the routine implementation of the 
heptavalent pneumococcal vaccine in Switzerland, were to 
define, as strictly as possible, the causative agents of 
pneumonia among children aged from 2 months to 5 years 
hospitalized for CAP on the basis of WHO clinical criteria, 
and to determine which factors could help clinicians to 
discriminate bacterial from viral pneumonia. 
Material and methods 
Study design and population 
Participation to this prospective and descriptive study was 
offered to ail consecutive children aged 2 months to 5 years 
old presenting with CAP according to the WHO criteria 
(Table 1) consecutively admitted to the children 's unit of 
the university hospitals of Lausanne and Geneva between 
March 2003 and December 2005. They were classified 
according to initial severity. Children with actively treated 
asthma, an underlying chronic disease, immunosuppres-
sion, or wheezing were excluded. Children with wheezing 
Table 1 Clinical definition of pneumonia according to the WHO 
Fever" Tachypneab Chest Not able 
Stage I (non-severe) 
Stage II (severe) 
+ 
+ 
Stage III (very severe) + 
a Fever~38°C axillary 
+ 
+ 
+ 
indrawing to drink 
and/or 
central 
cyanosis 
+ 
+ + 
bRespirat01y rate >50/min (2-11 months) and >40/min (1-5 years) 
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were specifically excluded because wheezing is considered 
to be a symptom of asthma and/or viral bronchiolitis and 
not of pneumonia, and therefore these children are not 
treated with antibiotics. Cough and fever, associated signs 
and symptoms, the use of antibiotics in the month before 
admission, and the main features of the clinical course were 
recorded. The Ethical committees of both institutions 
approved the study protocol. Signed consent was obtained 
from informed parents. 
Routine samples for inflammatory parameters 
On admission, a blood sample was taken for total white 
blood cell count (WBC) with manually verified differential 
count. Serum CRP and PCT (Lumitest®, Brahms, Berlin, 
Germany) were measured. 
Radiology 
A senior radiologist, blinded to clinical and laboratory 
findings, reviewed ail chest radiographs and assigned a 
standardized description of the X-ray as proposed by the 
WHO working group [5]: the presence of consolidation 
or pleural effusion with parenchymal infiltrate defined 
pneumonia. 
Microbiology 
On admission, before starting an antibiotic treatment, 
peripheral blood cultures, and during the winter epidemic, 
a rapid antigen detection test for RSV (Coris or Becton 
Dickinson), were performed. Within 8 h after admission, 
nasopharyngeal aspirates (NPA) were obtained after respi-
ratory physiotherapy for viral and bacterial culture, PCR 
analysis, and viral antigen detection. PCR analysis was 
performed for Mycoplasma pneumoniae and Chlamydia 
pneumoniae. RT-PCR assays were performed for 13 viruses 
including Influenza A and B, RSV A and B, Rhinovirus, 
Parainfluenza 1-3, enterovirus, human metapneumovirus, 
coronavirus OC43, E229, and NL 63 as previously 
described [15, 16, 25]. In the present study, all the assays 
were used as qualitative tools. PCR for M pneumoniae and 
C. pneumoniae were done by a multiplex real-time PCR 
according to Welti et al. [44]. Viral antigen detection was 
performed for Adenovirus, Para-influenza 1-3, RSV, and 
Influenza A and B by indirect immunofluorescence (Argene 
Antibodies) or ELISA. 
Serology 
Serum samples were taken at admission and approximately 
3 weeks after hospitalization, then stored at -20°C and 
subsequently transported on dry ice to the laboratories. The 
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laboratory was unaware of clinical data. Antibodies for 
Influenza A and B; Parainfluenza 1, 2, and 3; RSV; 
Adenovirns; and M pneumoniae were detected by the 
complement fixation method. Paired samples were tested in 
the same rnn. Acute infection was defined by a fourfold rise 
or a titer higher than 1/80. Serologic tests for C. pneumo-
niae were done by using a micro-immunofluorescence test 
(MRL Diagnostics). A fourfold rise between the acute and 
convalescent sera or an initial titer higher than fourfold the 
positive eut off value ( 1: 16) were considered as indicative 
of a recent infection, as previously described [26]. Sernm 
IgG antibodies to pneumolysin were measured by indirect 
ELISA on antigen-coated Immulon plates (Thermo Lab-
system), following 60 min incubation at 37°C. Results were 
compared to a pool of purified human immunoglobulins 
(Endobulin, Baxter) used as standard and expressed in 
ELISA Units/ml. Samples with a rise greater than twofold 
between acute or convalescent sera and/or acute sernm 
antibody titers greater than 300 EU/ml were scored 
positive. These limits have been previously demonstrated 
to be a reliable method for the serological diagnosis of 
pneumococcal exposure [22, 35]. 
Detection of Streptococcus pneumonia by PCR 
The blood samples were taken at the time of admission and 
sera were frozen at -70°C in order to be analyzed in a 
second phase. The detection of S. pneumoniae was 
performed by real-time PCR with the Taqman method. 
The specific target was the pneumolysin gene. Briefly, 
200 µl ofblood specimen were pre-lysed with 80 µ1 oflysis 
buffer (Bacterial lysis buffer, Roche Diagnostics) and with 
30 µ! of a cocktail of enzymes (Lyt030 enzymmix, Roche 
Diagnostic). After an incubation period of 30 min at 37°C, 
the sample was automatically extracted with a MagNa Pure 
compact instrument using the MagNa Pure compact 
isolation kit I. Five microliters of the eluted DNA were 
then amplified in triplicate with a Taqman ABI Prism 7700 
Sequence Detector (Applied Biosystems). Any significant 
curve before the cycle 40, was considered as a positive 
signal, the positive eut offwas defined as 1,000 copy/ml [8, 
27, 43]. 
Etiologie classification criteria 
The criteria for viral infection were a positive viral culture, 
viral antigen, positive viral serology, or viral PCR. A 
bacterial infection was considered if a blood culture, a 
pleural fluid culture, a pneumococcal PCR, or a serologic 
assay was positive. Atypical and typical bacteria were-
grouped together. Subjects with criteria of both viral and 
bacterial infections were considered to have infections of 
mixed etiology. 
Treatment 
Patients were treated with a course of parenteral antio-
biotics first (cefuroxime (n=46), ceftriaxone (n=22), 
amoxiclavulanic acid (n=38), floxapen (n= 1)), followed 
by oral antibiotics (amoxiclavulanic acid or cefuroxime) for 
a total duration of 2 to 25 days. Parenteral cefuroxime was 
initially associated with clarithromycin in four patients or 
switched for vancomycin and amoxyclavulanic acid or for 
amoxycillin and clindamycin in two patients with pleural 
effusion. 
Statistical analysis 
Data were analyzed using Epi Info 6.04d (Center for 
Disease Contrai and Prevention, Atlanta, GA, USA). 
Standard parametric and non-parametric statistical tests 
were done according to distribution and variance of studied 
variables. The level of statistical significance was defined 
as p:S0.05. Kappa statistics were computed using PAIRS 
module, version 1.33, of Pepi for Windows software. 
Results 
Population characteristics 
A total of 111 children were eligible during the study 
period. Ninety-nine children were finally enrolled (six 
patients were excluded because of the impossibility to 
obtain samples and, after initial consent, five parents 
decided to interrnpt the study). Among these patients, 51 
were females (52%). The average age was 29 months. 
According to WHO criteria, nine patients (9%) requiring 
hospitalization had non-severe pneumonia; 67 (68%) 
patients, severe pneumonia; and 23 (23%), very severe 
pneumonia. All subjects had fever or a recent history of 
fever and tachypnea. Many patients showed a number of 
other symptoms: 96 had cough (97%), 80 (81 %) had 
feeding difficulties, 45 (45%) had vomiting, and 17 (17%) 
abdominal pain. Other symptoms were tiredness or apathy 
(n=7); thoracic pain (11=5); or upper respiratory symptoms 
(URS): rhinitis (11=6), sore throat (11=3), and ear pain 
(n=2). The average temperature at admission was 39.1°C. 
Breath sounds were abnormal in 78 patients (79%) and 25 
(26%) were dehydrated. Antibiotics were given to 27 
patients (27%) during 30 days before hospitalization. 
Although there was a large variation in the number of 
monthly hospitalizations, no clear seasonal pattern was 
observed. The average duration of hospitalization was 
2 days ranging from a few hours to 25 days. Twenty-six 
children (26%) required supplemental oxygen therapy, nine 
patients (9%) needed a gastric feeding tube, and nine (9%) 
~ Springer 
a thoracic drainage. Three patients were transferred to the 
pediatric intensive care unit, two of them requiring non-
invasive assisted ventilation (Table 2). 
Overall results 
Table 3 shows the number of samples obtained for each 
test. Viral and atypical bacterial serology, were the most 
difficult to obtain (follow-up blood sample), as well as 
nasopharyngeal aspirates (NPA), notably in children with-
out upper respiratory tract involvement. A potential 
causative agent was detected in 85 (86%) of the 99 patients. 
Evidence of bacterial infection atone was demonstrated in 
Eur J Pediatr 
19 patients (19%) and viral infection alone in 33 (33%) 
cases. Mixed bacterial-viral infection was found in 33 
(33%) patients (Fig. 1 ). 
Bacterial infection 
Only one patient had a positive blood culture (S. pneumo-
niae), while three other blood cultures were contaminated 
by a coagulase-negative Staphylococci. One patient had a 
Group A (3-hemolytic Streptococcus in pleural fluid culture. 
Overall, bacteria with or without co-infecting pathogens 
were identified in 53% of the cases (52 patients). 
Pneumococcal pneumonia was diagnosed in 45 patients 
Table 2 Demographic and clinical results of 99 patients hospitalized for community-acquired pneumonia and con-elation with etiology 
Characteristics Total Bacterial Viral Mixed Unknown P Value 
pathogen 
No. of patient (%) 99 19 (19) 33 (33) 33 (33) 14 (14) 
Age, months (0.25; 0.75)" 29.4 (17; 48) 23.4 (19; 48) 25.1 (15; 38) 42.9 (24; 52) 22.4 (11; 34) 0.033c,e 
Gender (m/f) 48/51 11/8 17/16 14/19 6/8 0.692d 
Antibiotics before hospitalization 27 8 8 9 2 0.327d 
Pneumonia stage Ib (non-severe) 9 2 5 2 0 0.650d 
Pneumonia stage IIb (severe) 67 13 19 24 li 
Pneumonia stage IIIb (very severe) 23 4 9 7 3 
Temperature al admission (0.25; 0.75)" 39.1 (38.5; 39.8) 39.0 (38.5; 39.8) 39.2 (38.7; 39.8) 39.1 (38.3; 39.6) 38.8 (38.5; 39.5) 0.308 
Symptoms of painb,f 22 2 6 13 1 0.026d,g 
Vomitingb 45 8 13 18 6 0.634d 
URSb li 1 4 3 3 0.505d 
Dehydrationb 25 9 2 8 6 0.003d,h 
Oxygen requirementb 26 5 li 7 3 0.693d 
Radiological consolidationb 77 16 25 26 10 0.9lld 
CRP mg/l" 167 (60; 200) 200 (100; 204) 88 (21; 194) 200 (li 7; 250) 142 (23; 192) 0.009c,i 
PCT ng/ml" 6.0 (!; 14) 11.5 (5; 18) 2.0 (0.5; 7.5) 11.0(3; 18) 3.0 (0.5; 4) O.OJ8cj 
WBC count (G/L)" 15.0 (9; 21) 15.0 (li; 19) 12.0 (7; 21) 16.0 (10; 21) 15.5 (11; 18) 0.59lc 
Band forms (G/L)" 1.85 (0.6-3.8) 2.65 (1.3; 3.8) 1.4 (0.5; 2.6) 1.82 (1.0; 4.0) 1.31 (0.6; 3.1) 0.417c 
Duration of hospitalization, days" 2 (2; 4) 3 (2; 9) 2 (l; 4) 2 (2; 4) 2 (1; 3) 0.255d 
(0.25; 0.75) 
a The median value was used (25th quantile; 75th quantile) 
b Number of patients 
c The Kruskal-Wallis one-way analysis of variance was used 
d The Chi-square analysis was used 
e Fmther Krnskal-Wallis analyses showed that, after exclusion ofunknown pathogen, results were significant between viral and mixed pneumonia 
(P=0.017) but not between bacterial and mixed (P=0.143) or viral and bacterial (P=0.425) 
r Abdominal, dorsal or thoracic pain 
g Further Chi-square analyses showed that, after exclusion of unknown pathogen, results were significant between mixed and bacterial group (P= 
0.027), but not between mixed and viral group (P=0.057), neither between bacterial and viral group (P=0.461) 
hFurther Chi-square analyses showed that difference was significant between viral and bacterial (P=0.0004) or mixed (P=0.039) group but not 
between bacterial and mixed group (P=0.087) 
i Further Chi-square analyses showed that, after exclusion ofunknown'pathogen, results were significant between ail bacterial infections (bacterial 
+ mixed) and viral infections (P=0.003), but not between bacterial and mixed (P=0.803), neither between bacterial and viral (P=0.023). 
iFurther Chi-square analyses showed that, after exclusion ofunknown pathogen, results were significant between ail bacterial infections (bacterial 
+ mixed) and viral infections (P=0.009), but not between bacterial and mixed (P=0.805), neither between bacterial and viral (P=0.016) 
~ Springer 
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Table 3 Microbiological armamentaiium and number of samples performed 
Blood NPA NPA NPA NPA (M pneumoniae, 
culture (viral culture) (viral AG) (viral PCR) C. pnewnoniae PCR) 
Viral 
serology• 
Serology for M 
pneumoniae and 
Pneumoc. Pneumoc 
serologl PCR 
No. of exams 98 (99) 85 (86) 
(total=99) (%) 
No. of positive 1 (!) 15 (17) 
(%) 
•Convalescent serology 
b Acute and/or convalescent serology 
80 (81) 
12 (15) 
93 (94) 
59 (63) 
(46% overall), based on PCR (21/45, 47%), rising antibody 
titer ( 14/45, 31 % ), and/ or high antibody titers at admission 
(30/45, 66%). Despite a negative PCR, 53% (24/45) of 
patients had serological evidence of acute pneumococcal 
infection. The single child with a pneumococcal bacteremia 
had a positive PCR and serology. S. pneumoniae was 
diagnosed alone in 12 patients (63% of bacterial etiology). 
Mixed pneumococcal-viral infections occurred in 28 
patients (85% of mixed pneumonia), with a large spectrum 
of concomitant viruses (Table 4). 
Viral infection 
Overall, 66 among the 99 children (67%) had evidence of 
an acute viral infection (Fig. 2; Table 4). PCR was very 
sensitive to detect several viruses. In no patient with a 
negative viral PCR, could a viral infection be detected 
using another method. There was a significant relationship 
between age and etiological category (Table 2). 
Clinical or inflammatory parameters and etiology 
Excluding patients with undetermined etiology, univariate 
analyses showed that dehydration was the only clinical sign 
significantly more represented in the bacterial group of 
pneumonia. Indeed, 4 7% of children with bacterial pneumo-
nia, while only 24% in the mixed group and 6% in the viral 
pneumonia group (P=0.003), showed signs of dehydration, 
11 bacterial (single) 14 % 1J bacterial (multiple) 5% .1111 viral (single) 21% 
Cl viral (multiple) 12% Ili! mixed (33%) Clunknown (14%) 
Fig. 1 Aetiology of pneumonia in 99 hospitalized children. Five-
patients, in the bacterial group, had a dual bacte1ial pneumonia (four 
including S. pneumoniae and Mycoplasma pneumoniae, one including 
S. pneumoniae and Group A streptococcus) 
89 (90) 
8 (9) 
71 (72) 
17 (24) 
C. pneumoniae• 
71 (72) 98 (99) 97 (98) 
12 (17) 40 (41) 21 (22) 
(Table 2). Other symptoms were not significantly associated 
with etiology. In particular, URS were not significantly more 
frequent in the viral group. The proportion of patients in each 
clinical severity category (WHO stages) did not differ 
significantly according to etiology (P=0.698). Analysis of 
laboratory data showed that children with bacterial pneumo-
nia overall had higher inflammatory parameters: CRP and 
PCT values were significantly higher in the bacterial 
pneumonia group when mixed and bacterial pneumonia 
were analyzed together (Table 2). However, inflammatory 
indices were not statistically associated with clinical severity. 
For a eut offlevel of60 mg/l the sensitivity ofCRP was 88% 
but the specificity was low ( 44%). For a eut off level of 5 ng/ 
ml the sensitivity of PCT was 72% and the specificity 58%. 
Total white blood cell count and band forms were not 
significantly associated with etiology. The proportion of 
children treated with antibiotics before hospitalization, did 
not differ according to the etiological categmy (Chi square, 
P=.33). The average duration of hospitalization was related 
to clinical severity. 
Clinical and radiological data 
On admission, breath sounds were described as completely 
normal in 21 (21 %) patients. In 78 patients with abnormal 
auscultation, the most constant sign was diminished breath 
sounds (59 patients). Chest X-ray was abnormal in 97 of98 
patients (99%). Radiological consolidation was present in 
77 (79%) patients. Overall percent agreement between the 
presence of diminished breath sounds and radiological 
consolidation was 60.2% with a Kappa coefficient of 0.11 
(95% CI~0.07 to 0.29), confirming very poor agreement. 
There was no association between radiological description 
and severity or etiology of pneumonia. 
Discussion 
One hundred and eleven immunocompetent children, aged 
between 2 months and 5 years old, hospitalized for 
pneumonia, were studied prospectively to elucidate the 
~ Springer 
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Table 4 Pathogens identified in 99 hospitalized children with community-acquired pneumonia 
Pathogen No Co-infection Co-infection with bacteriaa Co-infection with virusesa Total no. of episodes, % 
Bacteria S. pneumoniae 12 10 28 45 (46) 
S. Group A f3 hemolytic 0 1 1 (1) 
M pneumoniae 2 5 5 11(11) 
C. pneumoniae 0 6 6 7 (7) 
Virus es Influenza A or B 0 8 10 14 (14) 
Parainfluenza 1-3 2 8 8 13 (13) 
Rhinovirus 7 11 10 20 (20) 
hMPV 5 5 7 13 (13) 
RSV A orB 6 3 7 13 (13) 
Enterovirus 8 11 13 (13) 
Adenovirus 0 6 5 7 (7) 
Coronavirus 0 4 7 7 (7) 
a The categories of co-infection with bacteria or with viruses are not mutually exclusive 
factors that could help the clinician to differentiate viral 
from bacterial pneumonia. Ninety-nine patients met the 
inclusion criteria in the strict respect of the WHO definition 
of pneumonia. A multiple diagnostic approach combining 
microbiology, serology, and biochemical assays was used to 
define the spectrnm of pathogens that cause pneumonia in 
children unimmunized against S. pneumoniae. Overall, a 
potential causative agent was detected in 86% of the 
children, confirming previous studies showing that the 
more tests are done, the more potential causes emerge [23, 
24, 31, 39]. Evidence of bacterial infection was demon-
strated in 53% of patients. 
S. pneumoniae was documented in 45% of the cases, 
corroborating previous reports such as the one by Michelow 
et al. [32]. A virns was found in 67% of the children. In 33% 
of the cases, a concurrent bacterial and viral infection was 
found. Antibiotic treatment before hospitalization doesn't 
seem to be a factor of misdiagnosis. Our study showed that 
in children fulfilling the WHO clinical definition of 
pneumonia and severity criteria, diagnosis was confümed 
by radiological consolidation in 78% of cases. The poor 
agreement between auscultation and radiological consolida-
tion confirms the poor sensitivity and specificity of auscul-
tation to diagnose pneumonia in young cliildren [ 11]. As 
previously described [14, 28] chest X-ray and blood cultures 
were not helpful in discriminating etiological categories of 
pneumonia. Duration of hospitalization was correlated with 
clinical severity essentially because WHO criteria define 
children with stage III pneumonia as requiring oxygen 
supplementation. Pain was the only clinical sign significantly 
associated with bacterial pneumonia. Acute-phase surrogate 
markers such as CRP and PCT, were significantly higher in 
bacterial infection regardless of the presence or absence of 
co-infecting viruses, corroborating several previous analyses 
[20, 33, 3 7] even if these findings are controversial in recent 
literature [ 13]. Further analysis is needed to determine the 
exact utility of these tests, as the sensibility and specificity 
with a bacterial eut off level were quite low. Finally, our data 
could not show a significant correlation between clinical 
severity and etiology of pneumonia [24]. 
As reported previously [12, 21, 40, 42], our data confüm 
the high prevalence of viruses and showed the frequent 
occurrence of co-infection in childhood CAP. The viruses 
most commonly found were rhinovirus (30%) and hMPV 
(20%), confirming the recent findings that these viruses 
frequently involved in pediatric CAP [3, 11, 3 6, 3 8]. RSV 
was less represented than in other reports [6], probably 
because all patients with typical bronchiolitis were strictly 
excluded. Severa! points still have to be elucidated: whether 
viruses are the direct cause of pneumonia, whether they 
Fig. 2 Distribution of virnses 
associated with pneumonia. A 
virus was found in 66 (67%) of 
the 99 patients hospitalized for 
pneumonia 
Dmultiple viruses (44%) llBRhinovirus (18%) DhMPV(9%) 
DEnterovirus (3%) 
lllllRSV (9%) 
l!lAdenovirus (3%) Olnfluenza A (6%) ll!lParainfluenza 1-3 (8%) 
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create conditions favoring secondary bacterial infections, or 
whether their presence plays a relatively minor role in CAP 
pathogenesis. 
The main limitation to our study is the lack of validation 
and standardization of all microbiological eut off values, 
especially those conceming S. pneumoniae [4]. One of the 
major obstacles to improve the understanding of CAP is 
probably that we are still underdiagnosing pneumococcal 
and possibly other bacterial pneumonia. The use of a single 
antigen (pneumolysin) for the serological diagnosis of 
pneumococcal pneumonia may be a limitation, as well as 
the difficulty, in our study, to obtain convalescent sernm 
samples (available for only 73% of the children). Therefore, 
it remains difficult to distinguish a real acquired infection 
from a recent colonization. As recently described by 
Nakayama et al. [34], the use of PCR to detect bacterial 
pneumonia could be a useful additional diagnostic method. 
However, the fact that 46% of young children with CAP 
requiring hospitalization demonstrated evidence of an acute 
pneumococcal infection, is in accordance with the demon-
strated impact ofpneumococcal immunization [10, 18, 29, 
30]. Finally, our results do not support the hypothesis that 
clinical severity depends on the causal agent. However, for 
ethical and practical reasons we chose to study only 
hospitalized children. Therefore, we have a limited number 
of patients with stage 1 pneumonia whom we usually treat 
in the ambulatory setting. A further study should include 
this group in order to confirm, with a greater number of 
patients, the non-association between clinical severity at 
admission and etiology. 
In conclusion, this study used strict WHO clinical 
criteria to select suitable subjects to undergo an extensive 
microbiological etiological workup using a complete set of 
modem diagnostic tools. Our<âata confirm a high preva-
lence of virnses and the frequent occurrence of co-infection 
in childhood CAP. Dehydration and surrogate markers of 
inflammation such as CRP and PCT were significantly 
higher in children with bacterial pneumonia. Therefore, 
further analyses should be performed in order to find out 
which children should be treated with antibiotics and in 
which children antibiotics could be withheld safely. The 
high proportion of S. pneumoniae in severe CAP re-
emphasized the importance of pneumococ~al immunization 
and antibiotics for treatment of CAP in young children. 
Other studies should also be perfmmed to evaluate the 
epidemiology of moderate to severe bacterial pneumonia 
after introduction of pneumococcal immunization. 
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